Incyte vs STERIS

Incyte (INCY), health care, and STERIS (STE), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

STERIS is worth $25B on the stock market and Incyte $24.3B: STERIS is valued at 3% more. Incyte trades at 60.8 times earnings and STERIS at 30.5; operating margins in their latest fiscal years were 29.5% and 18.6%. Over the past year Incyte's share price has moved +15.8% and STERIS's +1.91%.

Key facts

Incyte market value
$24.3B
STERIS market value
$25B
Incyte P/E
60.8
STERIS P/E
30.5
Incyte revenue
$5.1BFY to 2025-12-31
STERIS revenue
$5.9BFY to 2026-03-31
Superinvestors holding both
1

Market values as of .

Incyte vs STERIS: every measure side by side
Measure Incyte STERIS
SectorHealth CareHealth Care
Country United States Ireland
Fiscal year ends2025-12-312026-03-31
Size
Market cap$24.3Blower$25Bhigher
Revenue$5.1Blower$5.9Bhigher
Earnings$1.3Bhigher$782.3Mlower
Employees2,844lower17,937higher
Total assets$7Blower$10.7Bhigher
Valuation
P/E60.8higher30.5lower
P/S4.7higher4.2lower
P/B4.3—
Dividend yield0.00%—
Profitability
Operating margin29.5%higher18.6%lower
Balance sheet
Net assets$5.2Blower$7.2Bhigher
Total liabilities$1.8Blower$3.5Bhigher
Total debt—$1.9B
Cash on hand$3.1Bhigher$439.6Mlower
Price change
Today-0.98%higher-1.46%lower
1 year+15.8%higher+1.91%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (1)

STERIS only (0)

None of the tracked investors.

Percentages are each holding's share of that investor's reported portfolio (under "Both": Incyte / STERIS). Who owns INCY · Who owns STE

Further comparisons

Learn

Questions and answers

Which is bigger, Incyte or STERIS?

By market value, STERIS is the larger: $25B against $24.3B for Incyte. By revenue in its latest fiscal year, STERIS is the larger: $5.9B against $5.1B for Incyte.

Which has the higher P/E ratio?

Incyte: 60.8, against 30.5 for STERIS. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher operating margin?

Incyte: 29.5%, against 18.6% for STERIS. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which superinvestors own both Incyte and STERIS?

In their latest 13F filings, Joel Greenblatt holds both.

Cite this page

Funkfolio, “Incyte vs STERIS”, data as of 17 November 2026. https://funkfolio.com/compare/incy-vs-ste

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.